15.1% average weight loss
Average body weight fell 15.1% after 1 year on oral semaglutide.*
91% of people
Adults lost at least 5% of their starting weight after 72 weeks with tirzepatide injections.*
91% of women
91% of women said they had relief from menopause symptoms after 12 weeks of estradiol with a progestin.**
Sources and study details
* Rodriguez et al., JAMA Internal Medicine (2024): observational study of 18,386 matched adults receiving Ozempic (semaglutide) or Mounjaro (tirzepatide); 52% had type 2 diabetes. Figures describe Ozempic users still on treatment, not women-specific results. Actual doses were not verified; discontinuation ended follow-up for 52.5% of semaglutide users. Each milestone is a separately published estimate, including statistical imputation for missing weights, not a prorated annual result. Percentages represent cumulative loss from starting weight and should not be added together. Ozempic use for weight management is off-label. Results concern approved Ozempic injections, not LIV’s compounded formula, which is not FDA-approved; individual results vary.
* Notelovitz et al., Obstetrics & Gynecology (2000). Twelve-week randomized trial, 333 menopausal women across four doses and placebo. The card gives the week-four median reduction for oral micronized estradiol 1 mg, not the percentage of women helped or a guaranteed time to relief. Your prescribed product and strength may differ. Study dose is not an instruction for use. Comparison for the 86% fewer result: Half the women taking oral estradiol 1 mg had at least an 86% drop in moderate to severe hot flashes at week four. On placebo, half had at least a 52% drop. This oral estradiol study measured how much those episodes decreased, with different results at different doses.
** For 91%: Rovati et al., 1999, German trial of 262 women. The 50 mcg/day matrix patch arm included 133 women and cyclic medroxyprogesterone acetate. Its symptom-relief rate was 91%; the comparator reservoir-patch regimen reported 96%. Original study.
